How a Korean biotech startup is using AI to move drug discovery from trial-and-error to precision design
A close up of a protein structure model. PHOTO: UNSPLASH
For decades, drug discovery has relied on trial and error, with scientists testing thousands of molecules to find one that works. Galux, a South Korean biotech startup, is changing that by using AI to design proteins from scratch. This method, called “de novo” design, makes it possible to build precise new therapies instead of searching through existing ones.
The company recently announced a US$29 million Series B funding round, bringing its total capital to US$47 million.This significant investment attracted a substantial roster of institutional backers, including the Korea Development Bank (KDB), Yuanta Investment, SL Investment and NCORE Ventures. These firms joined existing investors such as InterVest, DAYLI Partners and PATHWAY Investment, as well as new participants including SneakPeek Investments, Korea Investment & Securities and Mirae Asset Securities.
At the core of the company’s work is a platform called GaluxDesign. Unlike many AI tools that only predict how existing proteins fold, this system uses deep learning and physics to create entirely new therapeutic antibodies. This “from scratch” approach lets the team go after so-called “undruggable” proteins. These are targets that traditional small-molecule drugs can’t reach because they lack clear binding pockets. By designing proteins to fit these complex shapes, Galux aims to unlock treatments that have stayed out of reach for decades. And that’s exactly why investors are paying attention.
The pharmaceutical industry is actively looking for faster and more efficient ways to develop new drugs, and Galux is built for exactly that. The company connects its AI platform directly to its own wet lab, where designs can be tested in real time. Each result feeds straight back into the system, sharpening the next round of models. This continuous loop speeds up discovery and improves precision at every step. It’s also why partners like Celltrion, LG Chem and Boehringer Ingelheim are already working with Galux.
Galux is no longer just trying to make drugs that stick to a target. The company now wants its AI to design medicines that actually work in the body and can be made at scale. In simple terms, a drug has to do more than bind to a disease—it must be stable, safe and strong enough to change how the illness behaves. Galux is moving into tougher targets such as ion channels and GPCRs. These play key roles in heart function and sensory signals. Ultimately, the goal is to show that AI-driven design can turn complex biology into real treatments. And instead of hunting blindly for a solution, the team is building exactly what they need.
Keep Reading
A closer look at PMMI’s FastTrack initiative and why it matters for growing manufacturing firms
Updated
February 5, 2026 1:49 PM
Cardboard boxes in a warehouse. PHOTO: UNSPLASH
Large trade shows are built for scale. But for small and medium-sized manufacturers, that scale often creates distance between what’s on display and what they can actually use. Too many options, too little time, and very few tools designed for companies that are still growing. That mismatch is what PMMI is trying to correct with its new SMB FastTrack Program at PACK EXPO East 2026.
That is the problem PMMI is trying to address with its new SMB FastTrack Program, launching at PACK EXPO East 2026 in Philadelphia.
PMMI — the Association for Packaging and Processing Technologies — is the industry body behind the PACK EXPO trade shows and a central organization in the global packaging and processing sector. Through FastTrack, it has created a program (not an app or a product) designed to help small and mid-sized companies navigate the show more efficiently and connect with solutions that fit their scale.
The idea behind SMB FastTrack is simple: reduce friction. Instead of asking smaller firms to sort through hundreds of exhibitors and sessions on their own, the program curates what is most relevant to them. Exhibitors that offer flexible pricing, right-sized machinery, or SMB-focused services are clearly identified with visual icons in both the online directory and on the show floor. That way, a small manufacturer can quickly distinguish between enterprise-only vendors and partners that are realistically accessible.
The same logic carries into education. Rather than treating all attendees the same, PACK EXPO East 2026 will include a learning track specifically built around SMB realities. These sessions focus on issues that smaller teams actually face—how to hire and train workers, use AI without over-investing, improve food safety, cut operating costs, and adopt technology in stages. The goal is not inspiration, but applicability: content that reflects real constraints, not ideal scenarios.
Planning, too, is built into the structure of the program. Through a dedicated FastTrack landing page, participants can access curated supplier lists, recommended sessions, and planning tools that help organize their time before they ever step onto the show floor. Tools like category search and sustainability finders are meant to narrow choices quickly, turning a massive event into something manageable.
Seen together, these elements point to a broader intention. PMMI is not simply adding features—it is reshaping how smaller manufacturers experience a major industry event. Instead of competing for attention in a space built for scale, SMBs are given clearer paths to the people, tools, and knowledge that match where they actually are in their growth cycle.
What makes SMB FastTrack notable is not the technology behind it, but the intention behind it. PMMI is recognizing that progress for small and mid-sized manufacturers depends less on spectacle and more on fit—solutions that are accessible, affordable, and adaptable. The program is designed to help companies move with purpose, not pressure.
In an industry where visibility often follows size, SMB FastTrack represents a structural shift. It treats small and medium-sized manufacturers not as a subset of the audience, but as a distinct group with distinct needs. By doing so, PMMI is quietly redefining what a trade show can be: not just a marketplace of innovation, but a usable platform for companies still building their next stage of growth.